Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Kromek secures extension of DARPA contract to detect ‘dirty bombs’, worth US$1.6mln

The radiation monitoring company said the extension will involve additional enhancements to its D3S equipment already deployed at DARPA
Measuring radiation
Kromek said 10,000 of its D3S units had already been delivered successfully

Kromek Group PLC (LON:KMK) has been awarded an extension of its high-volume production contract with the Defense Advanced Research Projects Agency (DARPA), an agency of the US Department of Defense.

The AIM-listed radiation monitoring company said the extension, worth US$1.6mln, will be delivered over an 18-month period and will involve additional enhancements to the company’s D3S equipment already deployed at DARPA.

READ: Kromek CEO confident of EBITDA break-even this financial year

Kromek added that its D3S products will be used to provide greater operational capability and information detail to DARPA’s SIGMA programme, an initiative aimed at preventing attacks involving radiological ‘dirty bombs’ and other nuclear threats in the US and globally.

Since the beginning of its contract in February 2016, Kromek said 10,000 of its D3S units had been delivered successfully.

Dr Arnab Basu, Kromek chief executive, said: "Having our D3S detectors positioned as a central pillar in DARPA's SIGMA programme is a testament to the capabilities of our state-of-the art technology and the strength of our relationship with DARPA.”

He added: “With field tests continuing in the US and across the globe, the D3S is gaining traction as an invaluable tool to help cities detect and counter the threat of dirty-bomb attacks."

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

self-driving car interior
February 16 2018
Ken Kroeger, executive chairman, is also upbeat about opportunities in truck fleets, aviation, rail and off-road
The D3S detector kit
Wed
Kromek, formerly Durham Scientific Crystals, was incorporated in April 2003 to commercialise technology that had been developed in the Physics Department of Durham University over a period of some 20 years.
Picture of hospital operating room
January 15 2018
Motif and Polarean are the two main areas of focus for Amphion Innovations

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use